Rossari Biotech reviews capex, delays Unitop and Tristar expansion rollout
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Subscribe To Our Newsletter & Stay Updated